Financial statements Geneme Molecular

Balance sheet of Geneme Molecular

Company age:

Age:

3 y. 11 m. 6 d.

Share capital:

5 000 PLN

Year	2021	2023
Total assets	197 349,51	437 499,59
A. Fixed assets	0,00	0,00
B. Current assets	197 349,51	437 499,59
C. Share capital contributions (basic funds)	0,00	0,00
D. Own shares (stocks)	0,00	0,00
Total liabilities	197 349,51	437 499,59
A. Equity	-86 863,53	15 711,73
B. Liabilities and provisions for liabilities	284 213,04	421 787,86
I. Long-term liabilities	69 894,79	74 985,64
II. Short-term liabilities	214 318,25	346 802,22

Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.

Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.